DISCUSSION
epithelioid sarcoma
PRIMARY TUMOR, DISEASE, SOFT TISSUE SARCOMA, EPITHELIOID SARCOMA
According to our knowledge, no existing epithelioid sarcoma prognosis prediction nomogram has been developed and validated before this study. Nomograms rely on easy‐to‐use digital interfaces, better accuracy, and more clear prognoses to help doctors make better decisions. Currently, nomograms are widely used in clinical work as prognostic devices. The prognostic predictors for the nomogram were age, primary tumor site, grade, surgery, T stage, and M stage. (Figure In terms of the ability to predict the prognosis of patients, we compared our prediction model with the TNM staging system. In training and validation cohorts, the C‐index was 0.818 and 0.832 for predicting OS, while the C‐index for TNM stage was 0.744 and 0.724. In terms of predicting the 1‐year, 3‐year, and 5‐year OS, the areas under the curves of our model are 0.846, 0.809, and 0.802, respectively, while the areas under the curves of TNM stages are 0.838, 0.777, and 0.784, respectively. From the results of the above, we can easily find that our model based on more clinical information has a better predictive effect than the TNM staging system.Using the SEER database, we created a prognostic model to determine the prognosis of ES patients based on large‐sample data. A total of 456 patients were enrolled in this study. This study supports previous research that elderly patients have a poorer prognosis.Our research shows that the model efficiently predicts the survival of patients with ES, thereby improving the accuracy of clinical decision‐making. There are some limitations to our study that should be noted. Firstly, stages were organized based on the 6th AJCC staging system, which could limit its effectiveness. Secondly, our nomogram was constructed based on the SEER database, where partial patient information is necessarily lost. As a result, there may be fewer qualified cases, which may increase the selection bias. Lastly, the study is a retrospective cohort study. In the current situation, given that ES is a very rare soft tissue sarcoma, the most reliable way to study the prognosis of this disease is using public database. Yet, the prognostic nomogram we constructed needs to be validated by further prospective cohort studies.